Year |
Citation |
Score |
2021 |
Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. PMID 34857535 DOI: 10.1212/WNL.0000000000013121 |
0.459 |
|
2020 |
Hehir MK, Rostedt Punga A, Ciafaloni E. Myasthenia Gravis Patient and Physician Opinions About Immunosuppressant Reduction. Muscle & Nerve. PMID 32129892 DOI: 10.1002/Mus.26850 |
0.548 |
|
2019 |
Machado P, Barohn R, McDermott M, Blaetter T, Lloyd T, Shaibani A, Freimer M, Amato A, Ciafaloni E, Burns T, Mozaffar T, Gibson S, Wicklund M, Saperstein D, Levine T, et al. P.02Phase 2/3 study of Arimoclomol in sporadic inclusion body myositis: study design Neuromuscular Disorders. 29. DOI: 10.1016/J.Nmd.2019.06.031 |
0.442 |
|
2015 |
Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, et al. Editorial by concerned physicians: Unintended effect of the Orphan Drug Act on the potential cost of 3,4-diaminopyridine. Muscle & Nerve. PMID 26662952 DOI: 10.1002/Mus.25009 |
0.523 |
|
2013 |
Hehir MK, Logigian E, Raja Rayan DL, Ciafaloni E. Double trouble in a patient with myotonia. Bmj Case Reports. 2013. PMID 23417379 DOI: 10.1136/Bcr-2012-008167 |
0.536 |
|
Show low-probability matches. |